Vildagliptin/metformin

Drug Profile

Vildagliptin/metformin

Alternative Names: Equmet; Eucreas; Galvumet; Galvus Met; Galvusmet; Icandra; LMF 237; Metformin/vildagliptin; Zomarist

Latest Information Update: 07 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Hanmi Pharmaceutical; Novartis; UCB
  • Class Antihyperglycaemics; Biguanides; Cycloparaffins; Insulin sensitisers; Nitriles; Polycyclic bridged compounds; Pyrrolidines
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Jan 2017 Novartis has patent protection for vildagliptin/metformin in Europe and Japan (Novartis 20-F filed in 2017)
  • 29 Aug 2016 Launched for Type-2 diabetes mellitus in Bangladesh (PO) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top